Our History

Creation of Thromb-X

In 1991, Prof Dr Désiré Collen and colleagues at the Katholieke Universiteit Leuven spun out Thromb-X nv. The Company's initial focus was in the cardio-vascular space. Collen, whose laboratory was the first to produce t-PA for clinical use was using part of the t-PA royalties received from Genentech to finance further developments. Thromb-X was looking at staphylokinase as it was thought to have efficacy similar to t-PA at a lower cost of goods. Later on, microplasmin (later ocriplasmin) was also looked at as a direct-acting thrombolytic. For the most part, and till 2006, the work has been financed with royalties from t-PA.

Thromb-X becomes ThromboGenics nv

Thromb-X becomes part of ThromboGenics nv. and operates as its R&D unit and seperate legal entity, untill its absorption in ThromboGenics nv in 2007 (IPO)

Creation of ThromboGenics Inc. in NYC, US

ThromboGenics nv setting up a subsidiary in the US, ThromboGenics Inc (NYC).

ThromboGenics NV listed on Euronext Brussels

ThromboGenics nv raises €35 million through a successful Initial Public Offering (IPO) and listed on Euronext Brussels (THR: €4,64).

ThromboGenics starts development of ocriplasmin for vitreo-retinal indications

Dr Patrik De Haes appointed CEO

ThromboGenics reports positive Phase III results with ocriplasmin for treatment of sVMA

September 2010 – Positive pivotal Phase III program with ocriplasmin, consisting of two trials in a total of 652 patients in the US and Europe, for the treatment of symptomatic Vitreomacular Adhesion (VMA).

ThromboGenics raises €56 million (private placement)

ThromboGenics raises €56 million (private placement)

ThromboGenics Inc. opens office in Iselin, NJ, US

Regulatory filing of ocriplasmin in Europe and the US

ThromboGenics submits regulatory filings for ocriplasmin in Europe and the US.

Ocriplasmin commercial license agreement signed with Alcon

ThromboGenics signs a strategic partnership with Alcon (Novartis) for the commercialization of JETREA® outside the United States.

What is this?

And this?

ThromboGenics raises €77.8 million (private placement)

FDA Priority Review for Ocriplasmin

FDA Priority Review for Ocriplasmin

FDA Advisory Committee Positive Recommendation for Ocriplasmin

FDA Advisory Committee Recommends ThromboGenics’ ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesion (VMA)

New England Journal of Medicine publishing ocriplasmin Phase III results

New England Journal of Medicine Paper publishes “Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Hole" (Phase III data)

US FDA Approval for JETREA

US FDA Approval for JETREA (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA)

SCRIP Award Licensing Deal of the Year 2012

ThromboGenics Lands SCRIP Award Licensing Deal of the Year 2012.

Commercial launch of JETREA® in the US

ThromboGenics, Inc kicks off JETREA® commercialization in the US – JETREA is globally the first and only pharmacological treatment option for treating symptomatic VMA.

CELL highlights potential of TB-403 (anti-PlGF) for treatment of medulloblastoma

CELL paper highlights potential of TB-403 (anti-PlGF) for treatment of medulloblastoma, a pediatric brain tumor 

EU approval for JETREA® (Ocriplasmin)

European Medicines Agency (EMA) approves ThromboGenics JETREA® (Ocriplasmin) for the Treatment of vitreomacular traction (VMT) including when associated with macular hole of diameter less than or equal to 400 microns

Alcon starts rolling out JETREA® in first markets outside US

Alcon is launching JETREA® in Denmark and Sweden, first market entries outside the US 

Health Canada approves ThromboGenics’ JETREA® for the treatment of symptomatic Vitreomacular Adhesion

Health Canada approves ThromboGenics’ JETREA® for the treatment of symptomatic Vitreomacular Adhesion

Germany’s G-BA confirms JETREA® to demonstrate significant therapeutic benefits

Germany’s G-BA confirms JETREA® to demonstrate significant therapeutic benefits for vitreomacular traction (VMT) patients, including when associated with macular hole.

NICE recommends reimbursement JETREA® in UK

National Institute for Health and Care Excellence (NICE) in the UK Recommends Reimbursing ThromboGenics’ JETREA®.

Prof Désiré Collen retires as Chairman of ThromboGenics nv.

Appointment of Dr Staf Van Reet as Chairman of the Board of Directors of ThromboGenics nv

Dr David Guyer (Ophthotech Corporation) appointed to ThromboGenics nv Board of Directors.

Dr David Guyer (Ophthotech Corporation) appointed to ThromboGenics nv Board of Directors.

Permanent US J-code (J7316) for JETREA®

Permanent US J-code, J7316 for JETREA®. US reimbursement full streamlined.

ThromboGenics’ JETREA® Nominated for 2014 Prix Galien USA

First Asian approvals for JETREA®

JETREA® Gains First Asian Approval in Malaysia

First Latin American approval for JETREA®

First Latin American approval for JETREA® in Uruguay

ThromboGenics decided to evaluate JETREA® for treatment of Diabetic Retinopathy

Decision to start evaluating Diabetic Retinopathy in the US. Phase II clinical trial preparations start.

Paul Howes apponted Executive Chairman ThromboGenics inc, Appointed Director to the BOD ThromboGenics nv.

Paul Howes apponted Executive Chairman ThromboGenics inc, Appointed Director to the BOD ThromboGenics nv.

 

Dominique Vanfleteren appointed Chief Financial Officer

Emmanuèle Attout appointed Independent Non-Executive Director of ThromboGenics nv

JETREA® approval in over 50 countries worldwide

JETREA® approval in over 50 countries, with patients being treated in over 20 countries globally

ThromboGenics presents positive topline results from ocriplasmin OASIS study

Positive Topline Results from ocriplasmin OASIS Study. OASIS Study Meets Primary Endpoint with 41.7% of Patients Treated with JETREA® achieving VMA resolution at Day 28 post injection (p<0.001) 24 month safety data in line with JETREA® approved label

EU Approval of New Ready Diluted Formulation of JETREA®

EU Approval for New Ready Diluted Formulation of JETREA®

ThromboGenics spins out oncology and creates Oncurious nv

ThromboGenics and VIB launch New Oncology Company Oncurious NV to develop TB-403 for Pediatric Brain Tumors (medulloblastoma) – Oncurious announces start of Phase I/IIa study, anticipating first patient in towards the end of 2015.

ThromboGenics evaluating JETREA® for treatment of Retinal Vein Occlusion (RVO)

ThromboGenics starts evaluating JETREA® for the treatment of Retinal Vein Occlusion (RVO) – Company Awarded €0.6 million IWT Research Grant

Philippe Baron Vlerick invests in ThromboGenics

Philippe Baron Vlerick confirms 3.6% shareholding

Oncurious NV appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor.

FDA accepts the Investigational New Drug (IND) Application for a Phase II study with JETREA® to treat non-proliferative diabetic retinopathy.

ThromboGenics presents full OASIS JETREA® trial data analysis (incl. ERG) and further real world Clinical Data at AAO 2015 in Las Vegas.

ThromboGenics enrolls the first patient in a Phase II CIRCLE Trial evaluating the potential of THR-409 (ocriplasmin)

Oncurious NV announces FDA acceptance of its Investigational New Drug (IND) Application for a Phase I/IIa study with TB-403 for treatment of pediatric brain tumors.

Oncurious NV and BioInvent Partner with US Research Consortium to accelerate Phase I/IIa clinical development of TB-403.